Jiangsu Hansoh Pharmaceutical Group Competitors and Similar CompaniesClear all

Jiangsu Hansoh Pharmaceutical Group's competitors and similar companies include Taiho Pharmaceutical, Shanghai Junshi Biosciences and Ethypharm.

	Jiangsu Hansoh Pharmaceutical Group Jiangsu Hansoh Pharmaceutical Group is a pharmaceutical company.	Taiho Pharmaceutical Taiho Pharmaceutical (大鵬薬品) is a company that researches, manufactures, and markets medicines, food supplements, and medical devices.	Shanghai Junshi Biosciences Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.	Ethypharm Ethypharm is a specialty pharmaceutical company focused on the treatment of pain and addiction.
Founding Date	Founding Date 1995	Founding Date 1963	Founding Date 2012	Founding Date 1977
Type	Type Public	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Lianyungang Shi, CN HQ	Locations Tokyo, JP HQ Oakville, CA Beijing, CN Nagoya, JP Okayama, JP Sendai, JP Tokyo, JP see more	Locations Shanghai, CN HQ	Locations Saint-Cloud, FR HQ Montréal, CA Châteauneuf En Thymerais, FR Nyons, FR Saint Cloud, FR see more
Employees	Employees 9,099	Employees 2,1591% decrease	Employees 2,5321% decrease	Employees 1,0001% increase
Financial
Revenue (est.)	Revenue (est.) ¥10.1b (FY, 2023)	Revenue (est.) ¥139.4b (FY, 2022)	Revenue (est.) ¥1.5b (FY, 2023)	Revenue (est.) N/A
Cost of goods	Cost of goods ¥664.5m (FY, 2023)	Cost of goods N/A	Cost of goods ¥541m (FY, 2023)	Cost of goods N/A
Gross profit	Gross profit ¥9.5b (FY, 2023)	Gross profit N/A	Gross profit ¥941.9m (FY, 2023)	Gross profit N/A
Net income	Net income ¥3.3b (FY, 2023)	Net income ¥5.1b (FY, 2022)	Net income (¥2.5b) (FY, 2023)	Net income N/A